European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	108
Early initiation of SGLT2 inhibitors after acute myocardial infarction	86
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	76
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	61
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	53
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead	51
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus	48
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	47
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	47
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	44
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study	40
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study	40
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	37
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	36
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	34
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	30
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	29
All about clinical trials	28
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	28
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data	28
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	27
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	26
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	26
New ways of mitigating aldosterone in cardiorenal disease	25

Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	25
When randomization is not enough: divergent β-blocker trials and the illusion of universal causality	25
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al .	24
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	24
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention	24
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	24
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	23
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients	22
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation	22
Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy	21
SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions	21
Cardiovascular prevention and risk factors	21
Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors	20
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	20
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	19
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	19
De-escalation versus shortening of dual antiplatelet therapy	19
From “bridging specialties” to “owning the patient”: rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care	18
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	18
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	18
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	18
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	17
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	17
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	17
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	17
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	16
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	16
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	16
Entering a new era of antiplatelet therapy: the 4D-ACS trial	16
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	16
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’	16
Are NOACs always the best strategy in elderly AF patients?	16
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study	15
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	15
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy	15
What's new in pharmacotherapy at ESC Congress 2023?	15
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	15
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	14
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	14
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome	14
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study	14
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	14
Different aspects of pharmacological heart failure treatment	14
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	14
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	13
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	13
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	13
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF	13

Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	13
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	13
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials	13
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	13
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	13
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions	13
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation	12
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	12
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	12
RNA-targeted therapeutics in cardiovascular disease: the time is now	11
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	11
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	11
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials	11
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	11
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	11
Kidney function and acid–base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial	11
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	10
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence	10
FLOW trial stopped early due to evidence of renal protection with semaglutide	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	9
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF	9
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	9
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	9
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	9
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	9
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	9
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial	8
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	8
Management of dyslipidaemia in patients with comorbidities: facing the challenge	8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug	8
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	8
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation	8
Special focus on the new anti-diabetic drugs	8
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	8
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI	8
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	7
Early DAPT discontinuation after acute myocardial infarction: finding the optimal TARGET	7
The role of cangrelor in acute and high-risk PCI settings	7
Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RA	7
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation	7
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	7
LDL lowering effect of PCSK9 inhibition is reduced in women	7
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	7
Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI	7
API-CAT investigators’ decisions on anticoagulation following extended treatment for cancer-associated thrombosis	7
Different aspects of myocardial intervention and pharmacological treatment	7
Lipid treatment	7
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	7
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT	7
Correction to: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	7
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis	6
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	6
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	6
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	6
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	6
The search for the perfect antiplatelet treatment continues	6
Our knowledge about atrial fibrillation steadily increases	6
Beta-blockers after myocardial infarction: indication, ejection fraction, and de-escalation pathway	6
Why Cardio-Rheumatology?	6
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	6
Pharmacogenetic testing to broaden patient eligibility for mavacamten	6
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	6
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	6
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	6
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study	5
Reply to ‘Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction’	5
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study	5
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure	5
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	5
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	5
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	5
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	5
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	5
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy	5

Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study	5
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials	5
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study	5
End of the first decade of EHJ CVP	5
Innovation and constraints in cardiovascular pharmacotherapy	5
EHJCVP Reviewers 2022	5
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	5
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	5
Reaping the rewards of a simplified dosing regimen	5
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis	5
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	5
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	5
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	5
Mechanistic insights into SGLT2 inhibition in Takotsubo syndrome	5
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	5
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data	4
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational	4
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension	4
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	4
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	4
Sex-related differences in platelet aggregation	4
Post-operative atrial fibrillation and stroke after non-cardiac surgery: a systematic review and meta-analysis	4
Why does research integrity affect us all?	4
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	4
ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy)	4
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease	4
Bleeding and thrombosis	4
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants	4
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery (reply)	4
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	4
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	4
Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	4
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	3
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes	3
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials	3
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock	3
Oral anticoagulants and antiplatelet treatment in different settings	3
Subcutaneous furosemide in heart failure: a systematic review	3
Correction to: Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus	3
Beta-blockers after myocardial infarction: time to change the guidelines	3
Fibrates: one more lost paradise in lipid treatment	3
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	3
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	3
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	3